Structural characteristics and biological functions of RSPO3 protein

RSPO3 protein is a member of the R-spondin protein family, which includes four members: RSPO1, RSPO2, RSPO3, and RSPO4. The RSPO3 protein consists of approximately 270 amino acids, with a molecular weight of about 30 kilodaltons, and is a secreted glycoprotein. It contains two furin-like cysteine-rich domains, a thrombospondin domain, and a C-terminal region rich in basic amino acids. The furin-like domains are responsible for receptor binding and represent the core functional regions of RSPO3. The thrombospondin domain mediates protein-protein interactions, while the C-terminal region is involved in extracellular matrix anchoring. The RSPO3 gene is located on human chromosome 6q22.33, and its expression is regulated by multiple transcription factors. The protein exhibits varying expression levels across tissues, with higher expression in the placenta, skeletal muscle, and kidneys, and moderate expression in the brain and heart.

RSPO3 protein exerts its biological functions by interacting with multiple receptors. It binds to leucine-rich repeat-containing G protein-coupled receptors 4, 5, and 6 (LGR4/5/6), which belong to the LGR family and serve as high-affinity receptors for RSPO proteins. Upon binding to LGR receptors, RSPO3 enhances the activity of the WNT/β-catenin signaling pathway. The mechanism involves the formation of a complex between RSPO3 and LGR receptors, which synergizes with WNT receptors Frizzled and LRP5/6 to inhibit the activity of E3 ubiquitin ligases such as ZNRF3 and RNF43. Under normal conditions, ZNRF3 and RNF43 promote the ubiquitination and degradation of WNT receptors. RSPO3 stabilizes WNT receptor expression on the cell membrane by inhibiting these negative regulators, thereby amplifying WNT signaling. Additionally, RSPO3 can bind to cell surface heparan sulfate proteoglycans, forming local concentration gradients to enhance signal transduction efficiency.

RSPO3 protein plays a critical regulatory role in embryonic development. It participates in early embryonic patterning and organogenesis, particularly in placental development, skeletal formation, and muscle differentiation. Gene knockout mouse models reveal that RSPO3 deficiency leads to embryonic lethality, primarily due to placental vascular defects and cardiac abnormalities. In skeletal development, RSPO3 influences osteoblast differentiation and bone formation by modulating the WNT signaling pathway. During vascular development, RSPO3 mediates endothelial cell migration and lumen formation, playing a key role in establishing and remodeling vascular networks. Furthermore, RSPO3 regulates limb development, and its aberrant expression can cause limb malformations. These findings highlight RSPO3 as an indispensable regulatory factor in embryogenesis.

In adult tissues, RSPO3 protein contributes to maintaining homeostasis and facilitating regeneration. It is crucial in the intestinal stem cell niche, where it enhances WNT signaling to balance epithelial stem cell proliferation and differentiation. In bone tissue, RSPO3 regulates osteoblast and osteoclast activity, participating in bone remodeling. Within the vascular system, RSPO3 promotes endothelial cell survival and proliferation, aiding post-injury vascular regeneration. In the liver, RSPO3 modulates hepatocyte proliferation and supports repair processes after damage. In the hematopoietic system, RSPO3 influences hematopoietic stem cell self-renewal and differentiation, maintaining hematopoietic homeostasis. These functions position RSPO3 as a key molecule in tissue regeneration and repair research.

Aberrant RSPO3 expression is closely linked to various diseases. In oncology, RSPO3 gene fusions and overexpression can aberrantly activate the WNT pathway, contributing to colorectal, gastric, and endometrial cancers. RSPO3 rearrangements generate fusion proteins that autonomously activate WNT signaling, driving tumorigenesis independent of ligand stimulation. In vascular diseases, dysregulated RSPO3 expression is associated with vascular malformations and pulmonary hypertension. In skeletal disorders, RSPO3 signaling abnormalities alter bone density, influencing osteoporosis development. Genetically, RSPO3 mutations are linked to congenital limb malformations, including tibial aplasia and digit anomalies. These findings suggest RSPO3 as a potential biomarker and therapeutic target for multiple diseases.

Given its disease relevance, RSPO3-targeted therapies are under investigation. For cancer treatment, anti-RSPO3 antibodies block RSPO3-LGR binding to inhibit aberrant WNT signaling and tumor proliferation. Small-molecule inhibitors disrupt RSPO3-receptor interactions. In regenerative medicine, recombinant RSPO3 protein shows promise for repairing intestinal, bone, and liver injuries. Gene editing could correct RSPO3 mutations in genetic disorders, while RNA interference may suppress tumor progression by reducing RSPO3 levels. Although preclinical studies demonstrate efficacy, further validation of safety and effectiveness is required.

Nanjing UA-BioTech Co., Ltd. (UA-Bio) has independently developed "RSPO3 Protein, Human" (Catalog No.: UA040025), a high-quality recombinant protein reagent designed for organoid culture, stem cell self-renewal, and Wnt signaling research. This human R-spondin 3 (RSPO3) protein acts as a potent enhancer of the Wnt/β-catenin pathway by binding LGR4/5/6 receptors and zinc finger proteins (ZNRF3/RNF43) to regulate stem cell proliferation and differentiation. It serves as a standardized tool for constructing intestinal, gastric, and hepatic organoids, as well as for regenerative medicine studies.

Nanjing UA-BioTech specializes in delivering cutting-edge reagents for immunology, cell therapy, and drug discovery. For details on "RSPO3 Protein, Human" (Catalog No.: UA040025), including specifications, validation data, or application guidance, please contact us.